Pritelivir

Pritelivir

Names
Systematic IUPAC name N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide
Identifiers
CAS Number	348086-71-5 Y
3D model (JSmol)	Interactive image
ChemSpider	430613
KEGG	D12811
PubChem CID	491941
UNII	07HQ1TJ4JE Y
CompTox Dashboard (EPA)	DTXSID70188344
InChI InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) Key: IVZKZONQVYTCKC-UHFFFAOYSA-N InChI=1/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25) Key: IVZKZONQVYTCKC-UHFFFAOYAL
SMILES Cc1c(sc(n1)N(C)C(=O)Cc2ccc(cc2)c3ccccn3)S(=O)(=O)N
Properties
Chemical formula	C18H18N4O3S2
Molar mass	402.49 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020.